Skip to main content
BioSenic SA logo

BioSenic SA — Investor Relations & Filings

Ticker · BIOS ISIN · BE0974280126 LEI · 549300HFIIMTOP1DFR76 BR Professional, scientific and technical activities
Open in API
Filings indexed 968 across all filing types
Latest filing 2017-05-11 Interim / Quarterly Rep…
Country BE Belgium
Listing BR BIOS

About BioSenic SA

http://www.biosenic.com/

BioSenic SA is a biotechnology company focused on developing innovative treatments for autoimmune diseases, inflammatory conditions, and bone disorders. The company's core activities are centered on two main technology platforms: one based on arsenic trioxide (ATO) for its immunomodulatory properties, and another involving allogeneic cell therapy for tissue repair and regeneration. BioSenic's objective is to address significant unmet medical needs in the fields of regenerative and immune medicine by advancing its clinical assets through development.

Recent filings

Filing Released Lang Actions
PR_2017-05-1_BT_2017-Q1_EN_Final.pdf
Interim / Quarterly Report Classification · 95% confidence The document is a 'Business Update' for the first quarter of 2017, released on 11 May 2017. It contains specific financial highlights (cash used, operating loss, cash at end of period) and business/corporate updates. While it is a quarterly update, it is presented as a press release/business update rather than a full formal financial report (10-Q or equivalent). Given the inclusion of substantive financial data and management commentary for a specific interim period, it aligns best with the 'Interim / Quarterly Report' (IR) category, as it provides the necessary financial performance metrics for the quarter. Q1 2017
2017-05-11 English
PR_2017-05-1_BT_2017-Q1_FR_Final.pdf
Interim / Quarterly Report Classification · 100% confidence The document is a quarterly activity report ('rapport d'activité du premier trimestre') for Bone Therapeutics. It contains substantive financial data, including cash burn, operating loss, and cash position for the first quarter of 2017, as well as operational updates and management commentary. It is not merely an announcement of a report, but the report itself, fitting the definition of an Interim/Quarterly Report (IR). Q1 2017
2017-05-11 French
20170526_BOTHE_AGO_2017_Droits-actionnaires_FR.pdf
Proxy Solicitation & Information Statement Classification · 98% confidence The document explicitly discusses shareholder rights concerning the upcoming Ordinary General Meeting ('ASSEMBLEE GENERALE ORDINAIRE') scheduled for May 26, 2017. It details procedures for shareholders to add items to the agenda, submit proposals, and ask written questions prior to the meeting. This content directly relates to the preparatory materials and information provided to shareholders regarding a general meeting, which aligns perfectly with the definition of Proxy Solicitation & Information Statement (PSI), as it outlines the rights and procedures leading up to the vote/meeting. While it relates to an AGM, the focus is on the procedural rights (proposals, questions) rather than the final voting results (DVA) or the meeting presentation itself (AGM-R). It is a solicitation of information and procedural guidance for shareholders before the meeting.
2017-04-26 French
PR_2017-04-26_BT_Documents AG 2017_EN_Final.pdf
AGM Information Classification · 98% confidence The document explicitly announces that the 'preliminary documents for the Annual General Shareholder Meeting on 26 May 2017 have been made available.' It details the date, time, and location of the AGM, and states where the notice, agenda, and motions to vote can be consulted (website, headquarters, or upon request). Since the document is an announcement about the availability of AGM materials rather than the AGM materials themselves (like a proxy statement or voting results), and given its relatively short length (5745 chars), it fits the description of a Report Publication Announcement (RPA). It is not the full AGM presentation (AGM-R) or the Proxy Solicitation Information (PSI), but rather the notice that those documents are ready for review.
2017-04-26 English
Comptes annuels 2016 BT.pdf
Annual Report Classification · 95% confidence The document is a formal Belgian 'Comptes Annuels' (Annual Accounts) filing for Bone Therapeutics. It contains structured financial data, including a balance sheet ('Bilan après répartition'), lists of directors, and auditor information. While it is part of the annual reporting process, in the context of international financial databases, these standardized statutory filings are classified as Annual Reports (10-K equivalent for non-US entities) as they represent the official yearly financial performance and statutory disclosure. FY 2016
2017-04-26 French
20170526_BOTHE_AGO_2017_Droits-actionnaires_EN.pdf
AGM Information Classification · 98% confidence The document explicitly concerns the 'ORDINARY GENERAL MEETING OF THE COMPANY TO BE HELD ON 26 MAY 2017'. It details the rights of shareholders regarding adding items to the agenda, submitting proposals, and asking written questions prior to the meeting. These procedures and rights disclosures are characteristic of materials prepared for or in connection with an Annual General Meeting (AGM). While it contains procedural information that might overlap with a Proxy Statement (PSI), the focus on shareholder rights concerning the agenda and questions leading up to the AGM strongly points to AGM-related documentation, often distributed as part of the AGM notice or related materials. Given the options, AGM-R (AGM Information) is the most appropriate fit for materials detailing shareholder rights and procedures for the upcoming AGM.
2017-04-26 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.